Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

NCT04736823 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT04736823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04736823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 1, 2021
Completion date
December 31, 2026
Enrollment
265 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc